Overview

Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)

Status:
Completed

Trial end date:
2007-03-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to investigate the effect of roflumilast (APTA-2217) on lung function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily. The study duration consists of a baseline period (4 weeks) and a treatment period (24 weeks). The study will provide further data on safety, tolerability, and effectiveness of roflumilast.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Mitsubishi Tanabe Pharma Corporation